BKT-300 is a potent and selective inhibitor of Protein regulator of cytokinesis 1 (PRC1) with a Kd of 28.3 nM. It disrupts microtubule organization, inducing G2/M arrest, mitotic catastrophe, and caspase-3–dependent apoptosis, and shows promise as a research treatment for advanced acute myeloid leukemia (AML).